Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats

[1]  V. Escudero-Ortiz,et al.  Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia , 2014 .

[2]  J. Pérez-Ruixo,et al.  Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients , 2014, Cancer Chemotherapy and Pharmacology.

[3]  W. Ceelen,et al.  Intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis: Review of animal models , 2014, Journal of surgical oncology.

[4]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[5]  J. Pérez-Ruixo,et al.  [Stability study of oxaliplatin and doxorubicin for intraperitoneal administration with hyperthermia]. , 2014, Farmacia Hospitalaria.

[6]  Andrew C. Hooker,et al.  Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.

[7]  P. Sugarbaker,et al.  Pharmacology of perioperative 5‐Fluorouracil , 2010, Journal of surgical oncology.

[8]  D. Elias,et al.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Ferron,et al.  Pharmacokinetics of heated intraperitoneal oxaliplatin , 2008, Cancer Chemotherapy and Pharmacology.

[10]  M O Karlsson,et al.  Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.

[11]  A. Elgazzar,et al.  Hyperthermia Alters Kidney Function and Renal Scintigraphy , 2007, American Journal of Nephrology.

[12]  D. Querleu,et al.  Pharmacokinetics of Oxaliplatin During Open Versus Laparoscopically Assisted Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC): An Experimental Study , 2007, Annals of Surgical Oncology.

[13]  W. Hohenberger,et al.  A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis , 2005, BMC Cancer.

[14]  P. Sugarbaker,et al.  Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics , 2003, Cancer Chemotherapy and Pharmacology.

[15]  M. Grever,et al.  Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat , 2002, Cancer Chemotherapy and Pharmacology.

[16]  J. Pignon,et al.  Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  P. Sugarbaker,et al.  Pharmacokinetics of intraperitoneal oxaliplatin: Experimental studies , 2001, Journal of surgical oncology.

[18]  P. Sugarbaker,et al.  Successful management of microscopic residual disease in large bowel cancer , 1999, Cancer Chemotherapy and Pharmacology.

[19]  M. Flessner,et al.  Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. , 1997, Journal of the National Cancer Institute.

[20]  R. Sladen.  Effect of anesthesia and surgery on renal function. , 1987, Critical care clinics.